The U.S. Preventive Services Task Force (USPSTF) recommends four types of screening for cancers: lung cancer, colorectal cancer, breast cancer, and cervical cancer.

On December 24, Shanghai Government unveiled the "Work Plan for Developing Medical Artificial Intelligence (2025–2027)" to advance the deep integration of artificial intelligence (AI) with clinical medicine and promote the application of vertical large models in diagnostic support for testing and inspection.

OpGen disclosed on Friday that Nasdaq's listing and hearing review council has affirmed an earlier decision by a Nasdaq hearing panel to delist the company's stock.

The Bill & Melinda Gates Foundation awarded more than 500 new grants in the fourth quarter of 2024, many of which are related to diagnostic and omics projects. The following is a selection of notable grants:

Health Canada has granted approval to MedMira’s Multiplo Rapid TP/HIV Test, for HIV and syphilis in Canada.

CDC continues to expect the respiratory disease season will have a similar or lower number of combined peak hospitalizations due to COVID-19, influenza, and RSV compared to last season. This update assesses when peak hospital demand may occur. CDC will update this outlook again in February or as warranted by substantial changes in the spread of any of the three diseases.

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies.

Real-world data firm Cota said Thursday that it has teamed up with Guardant Health to provide biopharmaceutical researchers access to a combined database that will include its own electronic health record data and Guardant’s genomic testing results from cancer patients.

Illumina and Macrogen announced on Monday that they are collaborating to sequence and analyze 145,952 genomes as part of South Korea's National Bio Big Data project.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking systemic treatment. Based on preliminary data from the Company’s ongoing prospective development and validation study, Castle’s pipeline test has shown potential to identify a subset of patients with AD who have an increased likelihood to achieve a super response to targeted therapies, indicated by a 90% or greater reduction in Eczema Area and Severity Index (EASI) score (EASI90) at three months. Assuming successful validation, the Company currently expects to launch its pipeline test by the end of 2025.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has entered into a comprehensive strategic agreement with Graves Gilbert Clinic to manage the lab operations of its main full-service laboratory in Bowling Green, Kentucky, and its location in Glasgow, Kentucky.

Pertussis is a highly contagious acute respiratory disease that can last for several months and often causes epidemics.